• Explore /
  • Poster
  • / A multicenter phase III randomized double-blind placebo controlled trial of pravastatin added to first-line standard chemotherapy in patients with small cell lung cancer (SCLC).

A multicenter phase III randomized double-blind placebo controlled trial of pravastatin added to first-line standard chemotherapy in patients with small cell lung cancer (SCLC).

Abstract Poster

Authors

null

Michael Seckl

Charing Cross Hospital Trophoblastic Disease Centre, London, United Kingdom

Michael Seckl , Christian Ottensmeier , Michael H. Cullen , Peter Schmid , Lindsay E. James , Christina Wadsworth , Hannah Farrant , Dakshinamoorthy Muthukumar , Joyce Thompson , Susan Harden , Gary William Middleton , Kate Fife , Barbara Crosse , Paul Taylor , Iftekhar Khan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Small Cell Lung Cancer

Clinical Trial Registration Number

ISRCTN56306957

Citation

J Clin Oncol 31, 2013 (suppl; abstr 7595)

DOI

10.1200/jco.2013.31.15_suppl.7595

Abstract #

7595

Poster Bd #

29E

Abstract Disclosures

Similar Posters

First Author: Joachim Von Pawel

First Author: Jean H. Hoffman-Censits

First Author: Marina Chiara Garassino

First Author: Jacob Sands